Pathogen Inactivation for Multiplex Spatial Transcriptomics

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for detecting analytes in pathogen-comprising samples require DNA or RNA preparation, which limits analysis to high-safety level labs, and are inefficient in multiplex detection.

Innovation Solution

A method that inactivates pathogens within the sample without isolating RNA or DNA, allowing for multiplex spatial transcriptomics analysis outside high-safety level labs, using at least 20 different sets of analyte-specific probes and decoding oligonucleotides for sequential signal-encoding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If DNA or RNA isolation is performed for spatial transcriptomics analysis, then analysis can be conducted, but the analysis must be performed in high-safety level labs and requires complex preparation steps

Engineering Contradiction:
Improvesafety levelVSAvoidpreparation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and removes the pathogen from the sample through inactivation and removal steps, separating the pathogen removal function from the analyte detection function. This allows the analyte analysis to proceed without requiring high-safety level laboratory infrastructure, as the pathogen is eliminated before analysis begins

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent performs pathogen inactivation and removal as preliminary actions before spatial transcriptomics analysis. By inactivating and removing pathogens in advance (before the main analysis), the sample is prepared in a way that eliminates safety concerns while preserving analyte integrity for subsequent detection

Inventive Principle:
Principle #10Preliminary action

2Productivity

If multiple analytes are detected using traditional methods, then detection is possible, but the process requires multiple separate assays and is time-consuming

Engineering Contradiction:
Improvedetection throughputVSAvoiddetection time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent merges multiple analyte detection capabilities into a single spatial transcriptomics assay. By using probe sets with unique identifier sequences that can be detected through the same imaging and analysis pipeline, multiple analytes are detected simultaneously in one experiment rather than requiring separate assays for each analyte

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent creates a universal detection platform where a single spatial transcriptomics workflow can detect multiple different analytes. The probe design system allows any number of analytes to be targeted using the same basic detection methodology, making the system multi-functional and highly productive

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If directly labeled probe sets are used for sequential hybridization, then detection rounds can be performed, but the probe sets must be denatured after every detection round requiring multiple differently tagged probe sets

Engineering Contradiction:
Improvedetection flexibilityVSAvoidprobe set complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent introduces an intermediary system using unique identifier sequences on probes that do not require fluorescent labels. These identifier sequences serve as mediators that can be detected through hybridization with decoding oligonucleotides, eliminating the need to denature and re-tag probes between detection rounds. The identifier sequence acts as a stable intermediary that preserves analyte information through multiple detection cycles

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables efficient and flexible detection of multiple analytes in parallel, reducing the need for complex probe sets and signal oligonucleotides, while allowing analysis in lower-safety level labs.

Implementation Method 1

each set of analyte-specific probes specifically hybridizing to a different analyte

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises: (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T)

Methodology Applied
Scientific EffectHybridization:

Implementation Method 3

contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising: (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide

Methodology Applied
Scientific EffectHybridization:

Data Source

PatentEP4381096B1Method for detecting an analyte in a pathogen-comprising sample
Publication Date: 2025.05.28 RESOLVE BIOSCIENCES GMBH
  • EP4381096B1 patent drawingFigure 1~2
  • EP4381096B1 patent drawingFigure 3
  • EP4381096B1 patent drawingFigure 3

AI summary

The present disclosure pertains to novel multiplex methods and kits for detecting different analytes in a sample in parallel by sequential signal-encoding of said analytes. In particular, the present disclosure pertains to a method that results in inactivation of pathogens for in-situ spatial transcriptomics (e.g. Molecular Cartography) without the step DNA or RNA preparation prior to analysis.